Holdings in Company and PDMR Shareholding

January 04, 2017

Proteome Sciences plc (AIM:PRM) received notification from Vulpes Life Science Fund (“Vulpes”), of which Martin Diggle, a non-executive director of the Company, is a director and partner, that on 28, 29 and 30 December 2016, it purchased 265,000, 250,000 and 350,000 ordinary shares of 1 pence each (“Ordinary Shares”) respectively, at an average price of 5.74 pence per Ordinary Share (the “Transaction”). Following the Transaction, Vulpes (and Mr Diggle) have a beneficial interest in 53,838,125 Ordinary Shares, representing approximately 18.29% of the current issued share capital of the Company.

Back to News